Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery

Schizophrenia Research

Volumn 159, Issue 1, 2014, Pages 182-187

  Gray, Bradley E ^a   McMahon, Robert P ^a   Green, Michael F ^b,c   Seidman, Larry J ^d   Mesholam Gately, Raquelle I ^d   Kern, Robert S ^b,c   Nuechterlein, Keith H ^b,c   Keefe, Richard S ^e   Gold, James M ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MATRICS; MCCB; Regression; Reliable change; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE CHANGE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONFIDENCE LIMIT; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEARNING; MAJOR CLINICAL STUDY; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MEASUREMENT ACCURACY; MENTAL PERFORMANCE; PRACTICE EFFECT; REGRESSION ANALYSIS; RELIABLE CHANGE INDEX; SOCIAL COGNITION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; TEST RETEST RELIABILITY; TREATMENT RESPONSE; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

ADULT; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

EID: 84907979767     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.032     Document Type: Article

References (12)

1. Buchanan R.W., Keefe R.S., Lieberman J.A., Barch D.M., Csernansky J.G., Goff D.C., Gold J.M., Green M.F., Jackson L.F., Javitt D.C., Kimhy D., Kraus M.S., McEvoy J.P., Mesholam-Gately R.I., Seidman L.J., Ball M.P., McMahon R.P., Kern R.S., Robinson J., Marder S.R. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 2011, 69:442-449.
2. Crawford J.R., Howell D.C. Regression equations in clinical neuropsychology: an evaluation of statistical methods for comparing predicted and obtained scores. J. Clin. Exp. Neuropsychol. 1998, 20:755-762.
3. Davis C.E. The effect of regression to the mean in epidemiologic and clinical studies. Am. J. Epidemiol. 1976, 104:493-498.
4. First M.B., Spitzer R.L., Miriam G., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen 2002, New York State Psychiatric Institute, Biometrics Research, New York, NY.
5. Follman D.A. The effect of screening on some pretest-posttest test variances. Biometrics 1991, 1(47):763-771.
6. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64:1115-1122.
7. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R.I., Seidman L.J., Stover E., Marder S.R. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am. J. Psychiatry 2008, 165:221-228.
8. Heaton R.K., Temkin N., Dikmen S., Avitable N., Taylor M.J., Marcott T.D., Grant I. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch. Clin. Neuropsychol. 2001, 16:75-91.
9. Javitt D.C., Buchanan R.W., Keefe R.S., Kern R., McMahon R.P., Green M.F., Lieberman J., Goff D.C., Csernansky J.G., McEvoy J.P., Jarskog F., Seidman L.J., Gold J.M., Kimhy D., Nolan K.S., Barch D.S., Ball M.P., Robinson J., Marder S.R. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 2012, 136:25-31.
10. Keefe R.S., Fox K.H., Harvey P.D., Cucchiaro J., Siu C., Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr. Res. 2011, 125:161-168.
11. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T.E., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R.I., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
12. Temkin N.R., Heaton R.K., Grant I., Dikmen S.S. Detecting significant change in neuropsychological test performance: a comparison of four models. J. Int. Neuropsychol. Soc. 1999, 5:357-369.